Strong Uptake For Incyte Eczema Cream Despite Formulation Issue

Physicians Keen On Topical Therapy

04 May 2022

Ahead of pending regulatory decisions on both sides of the Atlantic for Opzelura, Incyte has reported promising progress for the JAK inhibitor in the highly competitive atopic dermatitis market.

Balloon — Smooth take-off for Opzelura • Source: Shutterstock

Incyte Corporation has been heralding the strong start in the US of the atopic dermatitis cream Opzelura, noting that it has moved quickly to resolve manufacturing issues that loomed over the launch of its topical JAK1/JAK2 inhibitor.

Opzelura, a topical formulation of Incyte's JAK inhibitor Jakafi/Jakavi (ruxolitinib) was approved for mild to moderate atopic dermatitis, also known as eczema, in September last year and the company's first quarter results show that despite having a black box warning reflecting the regulator’s concerns about the safety of the JAK class, the launch is going well. Net sales were $12

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

16 May 2025

• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

15 May 2025

• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

15 May 2025

• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

15 May 2025

• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.